急性髓系白血病中 T 细胞介导免疫的改变。
Alterations of T-cell-mediated immunity in acute myeloid leukemia.
机构信息
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
出版信息
Oncogene. 2020 Apr;39(18):3611-3619. doi: 10.1038/s41388-020-1239-y. Epub 2020 Mar 3.
Abstract
Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival. While some malignancies have seen improvements in clinical outcomes with immunotherapy, success of these agents in AML remains elusive. Despite limited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the immune system can improve overall survival of AML patients. Understanding the causes of immune evasion and disease progression will identify potential immune-mediated targets in AML. This review explores immunosuppressive mechanisms that alter T-cell-mediated immunity in AML.
摘要
急性髓系白血病（AML）是一种全身性、异质性的血液系统恶性肿瘤，总体生存率较差。虽然某些恶性肿瘤的免疫治疗在临床结局方面有所改善，但这些药物在 AML 中的疗效仍难以捉摸。尽管进展有限，但干细胞移植和供者淋巴细胞输注表明，免疫系统的调节可以改善 AML 患者的总体生存率。了解免疫逃逸和疾病进展的原因将确定 AML 中潜在的免疫介导靶点。本综述探讨了改变 AML 中 T 细胞介导免疫的免疫抑制机制。
相似文献
1
Alterations of T-cell-mediated immunity in acute myeloid leukemia.急性髓系白血病中 T 细胞介导免疫的改变。
Oncogene. 2020 Apr;39(18):3611-3619. doi: 10.1038/s41388-020-1239-y. Epub 2020 Mar 3.
2
A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.一种新型非放射性 CFDA 检测方法，用于监测髓性白血病中的细胞免疫反应。
Immunobiology. 2013 Apr;218(4):548-53. doi: 10.1016/j.imbio.2012.06.014. Epub 2012 Jul 2.
3
The progress and current status of immunotherapy in acute myeloid leukemia.急性髓系白血病免疫治疗的进展与现状
Ann Hematol. 2017 Dec;96(12):1965-1982. doi: 10.1007/s00277-017-3148-x. Epub 2017 Oct 28.
4
The potential role of the thymus in immunotherapies for acute myeloid leukemia.胸腺在急性髓系白血病免疫治疗中的潜在作用。
Front Immunol. 2023 Feb 6;14:1102517. doi: 10.3389/fimmu.2023.1102517. eCollection 2023.
5
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.在人类急性髓系白血病小鼠异种移植模型中对嵌合抗原受体T细胞进行优化清除。
Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.
6
Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.急性髓系白血病的免疫治疗干预措施
Cancer Treat Res. 2022;183:225-254. doi: 10.1007/978-3-030-96376-7_8.
7
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.对晚期血液系统恶性肿瘤患者进行非清髓性预处理的异基因造血细胞移植。
Cytotherapy. 2001;3(4):253-60. doi: 10.1080/146532401317070880.
8
Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.免疫疗法治疗急性髓细胞白血病（AML）：一种强有力的替代疗法。
Biomed Pharmacother. 2018 Jan;97:225-232. doi: 10.1016/j.biopha.2017.10.100. Epub 2017 Nov 6.
9
Advances in immunotherapy for acute myeloid leukemia.急性髓系白血病的免疫疗法进展。
Future Oncol. 2018 Apr;14(10):963-978. doi: 10.2217/fon-2017-0459. Epub 2018 Mar 15.
10
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.基于 T 细胞的急性髓系白血病免疫疗法：当前概念和未来发展。
Leukemia. 2021 Jul;35(7):1843-1863. doi: 10.1038/s41375-021-01253-x. Epub 2021 May 5.
引用本文的文献
1
Dysregulated Immune Responses in Sepsis: Insights From Treg-Related Gene Expression.脓毒症中失调的免疫反应：来自调节性T细胞相关基因表达的见解
J Inflamm Res. 2025 Aug 27;18:11689-11702. doi: 10.2147/JIR.S523019. eCollection 2025.
2
Impact of single nucleotide polymorphisms of immunomodulatory factors on treatment response and prognosis in acute myeloid leukemia.免疫调节因子单核苷酸多态性对急性髓系白血病治疗反应和预后的影响。
Front Immunol. 2025 Mar 31;16:1571332. doi: 10.3389/fimmu.2025.1571332. eCollection 2025.
3
H2-K1 protects murine leukemia stem cells from natural killer cell-mediated immune surveillance.H2-K1保护小鼠白血病干细胞免受自然杀伤细胞介导的免疫监视。
Haematologica. 2025 Jun 1;110(6):1389-1394. doi: 10.3324/haematol.2024.286468. Epub 2025 Jan 23.
4
Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia.抗 PD-1 联合低甲基化剂和 CAG 方案桥接异基因造血干细胞移植：复发/难治性急性髓系白血病的新策略。
Front Immunol. 2024 Aug 16;15:1409302. doi: 10.3389/fimmu.2024.1409302. eCollection 2024.
5
Study on leukapheresis of hyperleukocytic acute myeloid leukemia through in vitro centrifugation.通过体外离心法对高白细胞急性髓系白血病进行白细胞分离术的研究。
BMC Cancer. 2024 Jul 24;24(1):888. doi: 10.1186/s12885-024-12644-5.
6
Association of Polymorphisms in PD-1 and LAG-3 Genes with Acute Myeloid Leukemia.PD-1 和 LAG-3 基因多态性与急性髓系白血病的关系。
Medicina (Kaunas). 2024 Apr 26;60(5):721. doi: 10.3390/medicina60050721.
7
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.AML/T 细胞相互作用组学揭示了与患者预后相关的因素，以及 ICAM1 在 T 细胞杀伤 AML 中的关键作用。
Leukemia. 2024 Jun;38(6):1246-1255. doi: 10.1038/s41375-024-02255-1. Epub 2024 May 9.
8
The KIR2DL family serves as prognostic biomarkers and correlates with immune infiltrates in acute myeloid leukaemia.KIR2DL 家族可作为急性髓系白血病的预后生物标志物，并与免疫浸润相关。
J Cell Mol Med. 2024 Apr;28(8):e18256. doi: 10.1111/jcmm.18256.
9
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.单细胞 CD4 和 CD8 T 细胞分泌组谱分析揭示免疫检查点阻断治疗后急性髓系白血病的时间和龛位差异。
Cancer Res Commun. 2024 Mar 6;4(3):671-681. doi: 10.1158/2767-9764.CRC-23-0402.
10
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.异基因造血干细胞移植后 AML 患者的缓解状态与独特的骨髓单个核细胞 T 细胞特征有关。
Blood. 2024 Mar 28;143(13):1269-1281. doi: 10.1182/blood.2023021815.
本文引用的文献
1
Editor's Note: Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism.编者按：雌激素受体α通过重编程胆碱代谢促进乳腺癌。
Cancer Res. 2019 Oct 15;79(20):5458. doi: 10.1158/0008-5472.CAN-19-2632.
2
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.Gal9/Tim-3 的表达水平在化疗失败的 AML 患者中更高。
J Immunother Cancer. 2019 Jul 10;7(1):175. doi: 10.1186/s40425-019-0611-3.
3
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.单细胞 RNA-Seq 揭示与疾病进展和免疫相关的 AML 层次结构。
Cell. 2019 Mar 7;176(6):1265-1281.e24. doi: 10.1016/j.cell.2019.01.031. Epub 2019 Feb 28.
4
Cellular immunotherapy for acute myeloid leukemia: How specific should it be?急性髓系白血病的细胞免疫治疗：应该有多特异性？
Blood Rev. 2019 May;35:18-31. doi: 10.1016/j.blre.2019.02.001. Epub 2019 Feb 23.
5
New Treatment Options for Acute Myeloid Leukemia in 2019.2019年急性髓系白血病的新治疗选择
Curr Oncol Rep. 2019 Feb 4;21(2):16. doi: 10.1007/s11912-019-0764-8.
6
Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype.吲哚胺2,3-双加氧酶的过表达与核型正常的急性髓系白血病患者的调节性T细胞表型相关。
Blood Res. 2018 Dec;53(4):294-298. doi: 10.5045/br.2018.53.4.294. Epub 2018 Dec 17.
7
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?免疫疗法在急性髓系白血病和骨髓增生异常综合征中的应用：新时代的曙光？
Blood Rev. 2019 Mar;34:67-83. doi: 10.1016/j.blre.2018.12.001. Epub 2018 Dec 5.
8
A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.一项多中心研究调查了发生继发性噬血细胞性淋巴组织细胞增生症的多系统朗格汉斯细胞组织细胞增生症患者。
Cancer. 2019 Mar 15;125(6):963-971. doi: 10.1002/cncr.31893. Epub 2018 Dec 6.
9
New drugs for acute myeloid leukemia inspired by genomics and when to use them.基于基因组学的急性髓系白血病新药及其应用时机
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):45-50. doi: 10.1182/asheducation-2018.1.45.
10
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.阿扎胞苷和纳武利尤单抗治疗复发/难治性急性髓系白血病的疗效、安全性和生物标志物：一项非随机、开放标签、Ⅱ期研究。
Cancer Discov. 2019 Mar;9(3):370-383. doi: 10.1158/2159-8290.CD-18-0774. Epub 2018 Nov 8.
Zotero 插件